Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2015

View Archived Issues

Strategic Science and Technologies begins phase I study of topical sildenafil

RiVax ricin toxin vaccine protective in macaque model

Bio-Path initiates phase II trial of BP-100-1.01 in patients with AML

Panoptes Pharma concludes license agreement with Mediolanum for PP-001

Vaxxas' Series B financing to fund vaccine development

Hyperion initiates pediatric study of Ravicti for urea cycle disorders

Apellis Pharmaceuticals begins phase I testing of APL-2

Galapagos, Rega Institute and University Hospital of Heidelberg receive HBV therapy grant

Novo Nordisk funds diabetes research at Karolinska Institutet

Repurposed sorafenib shows promising antiviral activity

Emergent BioSolutions presents results of phase II study of AV-7909 for anthrax

Actelion patents LXA4R agonists

NeED Pharma presents new viral entry inhibitors

Italian and U.S. scientists disclose dual FAAH inhibitors/DRD3 modulators

MMV, Drexel University and University of Washington patent new antimalarials

Novartis patent reports new complement factor B inhibitors

GSK acquires vaccine company GlycoVaxyn

FDA grants orphan drug designation to Reolysin for ovarian cancer

Heron Therapeutics begins phase I study of HTX-011

Valneva completes Dukoral acquisition

Enzo Biochem develops flow cytometry assay for cervical cancer prognosis

FDA advisory committees set date to jointly review talimogene laherparepvec BLA

AbbVie seeks Japanese approval for oral two direct-acting antiviral treatment for HCV

Anika Therapeutics files for U.S. and E.U. approval of Cingal for osteoarthritis of the knee

Synthetic Biologics reports topline data from phase Ib trial of SYN-004

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...